title: Imaging surveillance of differentiated thyroid cancer.
abstract: Intensive imaging surveillance has resulted in the ability to detect small-volume, often clinically occult, residual or recurrent disease. For most patients with differentiated thyroid cancer (DTC), such findings are unlikely to have an impact on disease-specific survival but our ability to predict which patients are at greatest risk and should receive the most aggressive therapies is surpassed by our ability to detect recurrence. Thus, the optimal treatment and surveillance regimens will surely continue to evolve as our ability to predict tumor behavior and aggressiveness improves. This article explains the rationale underlying current surveillance strategies and the utility and implications of imaging findings that are critical for the appropriate care of patients with DTC.
authors.affiliation: Division of Abdominal Imaging, Department of Radiology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Suite 3950 PST, Pittsburgh, PA 15213, USA. johnsonna2@upmc.edu
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Johnson
authors.forename: Shane O
authors.initials: SO
authors.lastname: LeBeau
authors.forename: Mitchell E
authors.initials: ME
authors.lastname: Tublin
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D044963:Biopsy, Fine-Needle; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D007457:Iodine Radioisotopes; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D018365:Neoplasm, Residual / Q000175:diagnosis; D011237:Predictive Value of Tests; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000628:therapy; D051598:Whole Body Imaging
chemical_list: D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D013954:Thyroglobulin